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The introduction of new technologies such as tandem mass spectrometry (MS/MS) has lead to a major rev-
olution in newborn screening for metabolic diseases: from “a test for a disease” (i.e. Guthrie test) to “a test
for many diseases”. On a single drop of blood it is now possible to analyze and quantify various metabo-
lites, not only acylcarnitines and amino acids, but also adenosine and 2’-deoxyadenosine (for the detection of
ADA-SCID) and lysosomal enzymes. Therefore a great potential can be seen in near future for the diagnosis of
diseases for which there may be a specific and effective therapy.
© 2013 Elsevier Ireland Ltd. All rights reserved.
The introduction of new technologies such as tandem mass
spectrometry (MS/MS) has lead to a major revolution in newborn
screening programs: from the old wiew “a test for a disease”
(i.e. Guthrie test) to the new concept “a test for many diseases”.
Using a single drop of blood on Guthrie card (DBS, dried blood
spot), indeed, it is now possible to search and quantify various
metabolites (acylcarnitines, amino acids) at the same time, thus
diagnosing numerous metabolic diseases: organic acidurias, fatty
acids beta-oxidation defects, aminoacidopathies, urea cycle defects.
From the late Nineties newborn screening programs experiences in
various Countries (Australia, USA, United Kingdom, Germany) made
possible the diagnosis of metabolic diseases in neonatal age, often
in a pre-symptomatic phase [1].
These diseases are rare individually, but show a high frequency
when considering them as a group. If not correctely diagnosed, they
can lead quickly to death, or cause severe neurologic impairment.
Early diagnosis by newborn screening allows the begin of the
therapy in a pre-symptomatic phase, than to performing a genetic
counseling. For these group of diseases, therapy consists in avoiding
prolonged fast (i.e. beta oxidation defects) and/or following a
dietary regime (i.e. low provision of natural protein or fat) and,
in some cases, supplementation with specific formulas. Other
possibles therapies are vitamines and/or drugs [2].
After a pilot study performed in 2002, Metabolic diseases
Unit at Meyer Children’s hospital in Florence started to manage
the neonatal screening program using MS/MS since November
2004, for all the babies born in Tuscany. Since 2010, we also
provide neonatal newborn screening for all the babies born in
Umbria, with a total amount of 45,000 newborns screened per
year. To date, over 350,000 newborns had been analyzed, with
a diagnostic rate of 1:1800. In our experience, some diseases
considerated rare or non esistent show conversely an high incidence
in italian population. This is the case, for istance, of MCAD
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(medium chain acylCoA dehydrogenase) deficiency. This condition
can be associated to death after an acute illness, i.e. for Reye
syndrome, or even to Sudden infant death syndrome (SIDS). In
non-screened newborns and childrens, it is possible to hypotize a
missed diagnosis whenever a sudden and unexpected death occurs.
In Tuscany and Umbria (two regions in central side of Italy) MCAD
deficiency shows an incidence of 1:27,000 screened newborns;
diagnosed infants maintain to date good clinical condition by
following a simple dietary regime (regular meals and avoidance
of prolonged fasting, expecially during acute infectious illness).
Newborn metabolic screening programs are at the moment carried
on in numerous others italian regions, with full or partial coverage:
Liguria, Emilia Romagna, Campania, Sardinia, Lazio and Sicily.
Moreover, newborn screening in LC-MS/MS allows the diagnosis
of some inherited or acquired metabolic defects in the mother, i.e.
sistemic carnitine’s defect (which can be associated to cardiomy-
opathy) so maternal diagnosis can be considered another beneficial
effect of newborn screening programs. This is the case of maternal
methilmalonic acidaemia with hyperomocisteinaemia due to vita-
mine B12 deficit. Propionylcarnitine (C3) is a metabolite included
in newborn screening programs for the detection of propionic/
methilmalonic acidaemia and disorders of cobalamine metabolism.
In mothers, vitamin B12 deficiency may be due to malabsorption
or vegan diet. In newborns and infants, cobalamin deficiency is
mainly due to maternal vitamin deficiency and may be wors-
ened by prolonged exclusive breastfeeding. Severe haematologic,
metabolic and neurological disorders may occur in infants exclu-
sively breastfeed by mothers who follow a strict vegetarian diet.
We underline the importance of newborn screening with second
tier test (search for free methilmalonic acid on DBS) and combined
analysis of acylcarnitines and omocisteine on mother’s blood in all
cases of elevated C3. This approach allows a properly diagnosis
of unrecognized vitamin B12 deficiency in the mother. Therapy
with i.m. hydroxocobalamin in newborn and in the mother may
prevent potential damages. There is a debate on how many and
which diseases should be screened, but certainly the availability of
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an effective therapy in early stage is an important prerequisite for
introducing a disease in the panel. In 2006, The American College of
Medical Genetics (ACMG), a group made up of specialists in public
health, health policy, ethics, and other sectors involved in neonatal
screening, carried out a rewiew of the literature relative to neonatal
screening and indicated, among diseases that could be considered
for the inclusion in screening programs, some lysosomal storage
diseases (LSD) such as mucopolysaccaridosis type I (MPS I), Fabry
disease, Pompe disease and Krabbe disease [3]. Arguments in favor
of the inclusion of LSD in newborn screening panels have been
the increasing availability of therapies (i.e. enzyme replacement
theraphy, bone marrow transplant) [4] and the probable underesti-
mation, in some cases very substantial, of the LDS’ real prevalence
in world population [5]. In recent years, the widespread use of
DBS combined with MS/MS has constituted a turning point for the
analysis of lysosomal enzymes associated to some storage diseases
(Fabry, Gaucher, Pompe, Krabbe, Niemann-Pick A/B diseases and
Mucopolysaccharidosis I). It’s a strong, highly sensitive, rapid, cheap
and non ivasive method; it’s suitable for screening projects both in
the neonatal population that in high-risk populations, both for the
targeted analysis of patients with specific symptoms. A single DBS
allows multiple enzymatic analysis and, moreover, a high number
of samples can be analyzed simultaneously. In our laboratory whe
have therefore developed methods of enzyme assay using MS/MS
on DBS for the diagnosis of some LSD suitable to treatment:
Fabry disease (α-galactosidase), Pompe disease (α-glucosidase) and
Mucopolysaccaridosis type I (α-iduronidase) [6]. Numerous expe-
riences of newborn screening for lysosomal diseases have already
been reported in international literature. A recent study of MS/MS
enzyme assay for Fabry, Pompe and MPS I disease on 100,000
DBS from anonymous newborn showed a combined prevalence of
1:7500 (low enzyme activity confirmed with genetic molecular
test). [7]. The study concludes that simultaneous enzyme assay on
MS/MS can be introduced into neonatal screening panel, and that
this method has a predictive value equal to or better comparing
with the methods currently used for non-lysosomal diseases. In
2006, an italian study estimated the incidence of Fabry disease
diagnosed by newborn screening (fluorimetric test on DBS) to
be 1:3100 (on a population consisting of 37,104 male infants)
[5]. In Taiwan, Pompe disease was diagnosed by screening with
a prevalence of 1:33,333 (on a population of 132,000 screened
newborns; age at diagnosis 9–22 days) [8]. From follow-up analysis
of patients with Pompe disease there is an evidence that 100% of
the patients diagnosed by screening in a presymptomatic phase are
ventilator-free; on the contrary, 50% of the patients diagnosed in
a symptomatic phase (even those diagnosed within six months of
age) are ventilator-dependent [9]. Regarding European experiences,
a neonatal screening on DBS for four LSD (Pompe, Fabry, Gaucher
and Niemann Pick A/B) was conducted in Austria from January 2010
in 34,736 newborns [10]. The study identified positive samples
which were then correlated with a specific condition: 2 cases of
Gaucher disease, 4 cases of Pompe disease and 9 cases of Fabry
disease, with a complessive prevalence of 1:2315 births. Neonatal
screening by LC-MS/MS requires great organizational commitment,
and high laboratoristic and clinical experience. A positive test must
be followed by a rapid newborn recall, for laboratory confirmation
test and clinical treatment and follow up. New test and protocols
(i.e. for low birthweight newborns) have been developed and can
reduce the possibility of false positive and false negative tests, thus
avoiding unnecessary stress or misdiagnosis.
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